FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT C	OF CHANGES	IN BENEFICIAL	OWNERSHIP
-------------	-------------------	---------------	------------------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response 0.5

			of Section So(ii) of the investment Company Act of 1540	
Mane and Address of Reporting Person McGowan Mary (Last) (First) (Middle)		Person*	2. Issuer Name and Ticker or Trading Symbol <u>Esperion Therapeutics</u> , Inc. [ESPR]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
		TICS INC.	3. Date of Earliest Transaction (Month/Day/Year) 08/19/2015	X Officer (give title Other (specify below) below) Chief Medical Officer
(Street) ANN ARBOR (City)	MI (State)	48108 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		4. Securities A Disposed Of (I			Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
					Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock	08/19/2015		A		15,000 ⁽¹⁾	Α	\$0.00	15,000	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (right to buy)	\$57.54	08/19/2015		A		210,000		(2)	08/19/2025	Common Stock	210,000	\$0.00	210,000	D	

Explanation of Responses:

1. These shares were acquired pursuant to a restricted stock unit award under the 2013 Amended and Restated Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. 25% of the restricted stock units vest on June 15, 2016 and the remainder shall vest in equal quarterly installments over a three (3) year period thereafter, subject to continued service.

2. 25% of option vests on June 15, 2016 and the remainder shall vest in equal quarterly installments over a three (3) year period thereafter.

/s/ Richard B. Bartram, by power of attorney

08/21/2015

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Date